WallStSmart
VRAX

Virax Biolabs Group Limited Ordinary Shares

NASDAQ: VRAX · HEALTHCARE · BIOTECHNOLOGY

$0.15
+7.27% today

Updated 2026-06-05

Market cap
$1.35M
P/E ratio
P/S ratio
453.46x
EPS (TTM)
$-1.22
Dividend yield
52W range
$0 – $1
Volume
38.3M

Virax Biolabs Group Limited Ordinary Shares (VRAX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
0 of 4
Last 4 quarters
Avg EPS surprise
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
Most recent quarter

When is the next earnings report?

Reporting date
March 31, 2025
Consensus EPS estimate
$-0.33
Fiscal period ending
2025-03-31

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+76.0%
Last 1 reports
Positive reaction rate
100%
1 of 1 quarters
Largest single-day move
+76.0%
2025-12-02
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2025-12-02$-0.49$0.39$0.69+76.0%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-09-30$0.00$-0.49$1608.00-67.5%
2025-06-30$0.00$-0.76$1378.00
2025-03-31$-0.33
2024-09-30$0.00$-0.89$4953.00
2022-06-30$0.00$-0.03$-92865.00

Frequently asked questions

When does Virax Biolabs Group Limited Ordinary Shares report next earnings?

Virax Biolabs Group Limited Ordinary Shares (VRAX) is scheduled to report earnings on March 31, 2025. The consensus EPS estimate is $-0.33.

Has Virax Biolabs Group Limited Ordinary Shares beaten earnings estimates?

Virax Biolabs Group Limited Ordinary Shares has beaten Wall Street EPS estimates in 0 of its last 4 quarterly reports. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.

How does VRAX stock react to earnings?

VRAX has moved an average of +76.0% the day after earnings over its last 1 reports, finishing higher after 1 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.